Patrick Machado
CIK 1311210 · Chief Business Officer and CFO · last filed 2026-07-02
Patrick Machado is a Chief Business Officer and CFO who has filed 139 SEC Form 4 insider transactions across 16 companies since 2007. The most recent filing, for ALMS, was dated Jul 2, 2026. Across all open-market trades the lifetime net is +$27.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $10.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$10.27M
16
139
$27.09M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALMS | Director | 10,617 | $26.96 | $286.2K | $0 | 4 | 2026-07-02 |
| RCUS | Director | 44,300 | $27.19 | $1.20M | $0 | 8 | 2026-06-12 |
| XENE | Director | 2,645 | $65.03 | $172.0K | $0 | 7 | 2026-06-03 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | Director | 0 | $4.36 | $0 | $214.4K | 15 | 2025-12-10 |
| ACELYRIN, Inc. (SLRN) Delisted | Director | 14,675 | $2.27 | $33.3K | $0 | 3 | 2024-06-11 |
| CHIMERIX INC (CMRX) Delisted | Director | 10,000 | $8.54 | $85.4K | $70.8K | 10 | 2023-06-12 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | — | $76.01 | — | $0 | 4 | 2022-08-17 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 3 | 2020-09-28 |
| Urovant Sciences Ltd. (UROV) Delisted | 10%+ Owner | 22,860,013 | $16.24 | $371.25M | $38.75M | 9 | 2019-06-19 |
| Myovant Sciences Ltd. (MYOV) Delisted | 10%+ Owner | 40,765,599 | $26.98 | $1.10B | $42.50M | 2 | 2019-06-06 |
| SCYX | Director | 750 | $3.62 | $2.7K | $165.4K | 7 | 2019-01-04 |
| ENDOCYTE INC (ECYT) Delisted | Director | 0 | — | — | $0 | 3 | 2018-12-21 |
| ABUS | 10%+ Owner | — | $4.42 | — | $0 | 2 | 2018-01-16 |
| ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Director | — | — | — | $0 | 2 | 2017-06-21 |
| MEDIVATION, INC. (MDVN) Delisted | Director | 219,564 | — | — | -$54.43M | 52 | 2016-06-23 |
| MDV | Sr. Vice President and CFO | 486,123 | $17.70 | $8.60M | -$178.0K | 1 | 2007-03-20 |
Recent Filings
139 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | ALMS | Grant (A) | +3,553 | $0 | EDGAR |
| 2026-06-12 | RCUS | Grant (A) | +5,700 | $0 | EDGAR |
| 2026-06-03 | XENE | Mixed | +2,645 | $0 | EDGAR |
| 2025-12-10 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Mixed | −8,818 | $0 | EDGAR |
| 2025-08-01 | ALMS | Grant (A) | — | $0 | EDGAR |
| 2025-06-20 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-12 | RCUS | Grant (A) | +13,300 | $0 | EDGAR |
| 2025-06-06 | XENE | Grant (A) | — | $0 | EDGAR |
| 2025-05-23 | — | Disp (D) | −14,675 | $0 | |
| 2025-05-23 | ALMS | Grant (A) | +7,064 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.